During this time, we understand that access to Axumin PET/CT scans in hospitals may be challenging in some U.S. locations due to COVID-19, especially for vulnerable patients including those who are immunocompromised. In the Axumin Imaging Center Location Directory, hospitals are noted with the following icon:
We suggest contacting the imaging centers in your local area to confirm the ability to schedule a PET/CT scan as well as confirm compliance with the Centers for Disease Control and Prevention (CDC) COVID-19 guidelines, as well as any applicable local and state guidelines.
The imaging centers listed in the Axumin Imaging Locator Directory have agreed in writing to be included. This is not a list of every location in the United States that performs Axumin scans. This information is provided as a reference for physicians and patients, and is not intended to be an endorsement by Blue Earth Diagnostics, Inc. (BED). Patients should speak with their doctor to determine if an Axumin scan is the right option for them.
Axumin® (fluciclovine F 18) injection is a diagnostic imaging agent (sometimes called a radiotracer). Axumin is used along with a positron emission tomography (PET) imaging scan for men who have had prior treatment for prostate cancer and now have prostate specific antigen (PSA) levels that are elevated.
Most commonly reported adverse reactions are:
Tell your doctor if you have any side effect that bothers you or does not go away.
These are not all the possible side effects of Axumin. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.